Shares of DexCom, Inc. (NASDAQ:DXCM) have received a consensus recommendation of “Buy” from the twenty-one ratings firms that are currently covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a hold recommendation and sixteen have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $89.29.

Several equities analysts have commented on the company. Royal Bank Of Canada reiterated an “outperform” rating and set a $87.00 price target on shares of DexCom in a report on Tuesday, April 4th. BTIG Research downgraded DexCom from a “buy” rating to a “neutral” rating in a report on Wednesday, May 3rd. Oppenheimer Holdings, Inc. set a $98.00 price objective on DexCom and gave the company a “buy” rating in a research report on Wednesday, May 3rd. Canaccord Genuity reduced their price objective on DexCom from $95.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, May 3rd. Finally, B. Riley reissued a “buy” rating and issued a $95.00 price objective on shares of DexCom in a research report on Tuesday, May 2nd.

In related news, CEO Kevin R. Sayer sold 8,649 shares of the firm’s stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $68.39, for a total value of $591,505.11. Following the completion of the transaction, the chief executive officer now directly owns 347,329 shares of the company’s stock, valued at $23,753,830.31. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Richard Doubleday sold 3,182 shares of the firm’s stock in a transaction on Tuesday, May 23rd. The stock was sold at an average price of $68.29, for a total value of $217,298.78. Following the completion of the transaction, the executive vice president now directly owns 72,395 shares of the company’s stock, valued at $4,943,854.55. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 34,881 shares of company stock valued at $2,447,887. 1.70% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP raised its position in DexCom by 4.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 110,292 shares of the medical device company’s stock valued at $6,586,000 after buying an additional 4,682 shares in the last quarter. Renaissance Technologies LLC bought a new position in DexCom during the fourth quarter valued at about $8,217,000. Norges Bank bought a new position in DexCom during the fourth quarter valued at about $27,815,000. Teachers Advisors LLC raised its position in DexCom by 4.0% in the fourth quarter. Teachers Advisors LLC now owns 184,560 shares of the medical device company’s stock valued at $11,018,000 after buying an additional 7,050 shares in the last quarter. Finally, Highbridge Capital Management LLC bought a new position in DexCom during the fourth quarter valued at about $2,983,000.

Shares of DexCom (DXCM) opened at 69.52 on Monday. The firm’s market capitalization is $6.00 billion. The company has a 50-day moving average of $72.72 and a 200 day moving average of $75.51. DexCom has a 12-month low of $57.68 and a 12-month high of $96.38.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Tuesday, May 2nd. The medical device company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.06. DexCom had a negative return on equity of 32.94% and a negative net margin of 14.70%. The company had revenue of $142.30 million for the quarter, compared to the consensus estimate of $143.94 million. On average, analysts predict that DexCom will post ($0.72) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “DexCom, Inc. (DXCM) Receives Average Rating of “Buy” from Analysts” was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/07/24/dexcom-inc-dxcm-receives-average-rating-of-buy-from-analysts.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.